{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:04:18Z","timestamp":1758474258631,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,8]]},"DOI":"10.7759\/cureus.91830","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:06:14Z","timestamp":1757336774000},"source":"Crossref","is-referenced-by-count":1,"title":["Sudden-Onset Severe Thrombocytopenia Secondary to Trimethoprim-Sulfamethoxazole"],"prefix":"10.7759","author":[{"given":"Jonathan","family":"Spadafora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Starcke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip F","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2013.05.005","article-title":"Approach to the diagnosis and management of drug-induced immune thrombocytopenia","volume":"27","author":"Arnold DM","year":"2013","unstructured":"Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, Kelton JG. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev. 2013, 27:137-45. 10.1016\/j.tmrv.2013.05.005","journal-title":"Transfus Med Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management","volume":"7","author":"Aster RH","year":"2009","unstructured":"Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009, 7:911-8. 10.1111\/j.1538-7836.2009.03360.x","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A188","article-title":"Severe thrombocytopenia possibly associated with TMP\/SMX therapy","volume":"36","author":"Yamreudeewong W","year":"2002","unstructured":"Yamreudeewong W, Fosnocht BJ, Weixelman JM. Severe thrombocytopenia possibly associated with TMP\/SMX therapy. Ann Pharmacother. 2002, 36:78-82. 10.1345\/aph.1A188","journal-title":"Ann Pharmacother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14937","article-title":"Frequency of lupus anticoagulant in COVID-19 patients","volume":"18","author":"Harzallah I","year":"2020","unstructured":"Harzallah I, Debliquis A, Dr\u00e9nou B. Frequency of lupus anticoagulant in COVID-19 patients. J Thromb Haemost. 2020, 18:2778. 10.1111\/jth.14937","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.21307\/immunohematology-2019-099","article-title":"Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms","volume":"30","author":"Curtis BR","year":"2014","unstructured":"Curtis BR. Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology. 2014, 30:55-65.","journal-title":"Immunohematology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.153","article-title":"Drug-induced thrombocytopenia: pathogenesis, evaluation, and management","author":"George JN","year":"2009","unstructured":"George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009, 153-8. 10.1182\/asheducation-2009.1.153","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427150-00007","article-title":"Drug-induced immune thrombocytopenia","volume":"27","author":"van den Bemt PM","year":"2004","unstructured":"van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf. 2004, 27:1243-52. 10.2165\/00002018-200427150-00007","journal-title":"Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/815907","article-title":"Trimethoprim-sulfamethoxazole-induced hyperkalemia in a patient with normal renal function","volume":"2012","author":"Nickels LC","year":"2012","unstructured":"Nickels LC, Jones C, Stead LG. Trimethoprim-sulfamethoxazole-induced hyperkalemia in a patient with normal renal function. Case Rep Emerg Med. 2012, 2012:815907. 10.1155\/2012\/815907","journal-title":"Case Rep Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.05.008","article-title":"Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders","volume":"52","author":"Kocak Z","year":"2006","unstructured":"Kocak Z, Hatipoglu CA, Ertem G, Kinikli S, Tufan A, Irmak H, Demiroz AP. Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders. J Infect. 2006, 52:e49-52. 10.1016\/j.jinf.2005.05.008","journal-title":"J Infect"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan D","year":"2010","unstructured":"Provan D, Stasi R, Newland AC, et al.. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010, 115:168-86. 10.1182\/blood-2009-06-225565","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007226","article-title":"Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study","volume":"6","author":"Chong S","year":"2022","unstructured":"Chong S, Zhao P, Huang RB, et al.. Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study. Blood Adv. 2022, 6:4320-9. 10.1182\/bloodadvances.2022007226","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.576","article-title":"Drug-associated thrombocytopenia","volume":"2018","author":"Bakchoul T","year":"2018","unstructured":"Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2018, 2018:576-83. 10.1182\/asheducation-2018.1.576","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404841-sudden-onset-severe-thrombocytopenia-secondary-to-trimethoprim-sulfamethoxazole","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:06:15Z","timestamp":1757336775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404841-sudden-onset-severe-thrombocytopenia-secondary-to-trimethoprim-sulfamethoxazole"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.91830","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}